Year archive

Active Biotech — 2013 filings

All 58 regulatory filings released by Active Biotech (ACTI) in 2013, sourced directly from the official regulator.

58 Filings

2013 Period

2013 filings (58)

Filing	Released	Lang
Laquinimod CHMP/EMA Opinion Regulatory Filings	2013-12-20	English
Laquinimod CHMP/EMA utlåtande Legal Proceedings Report	2013-12-20	Swedish
Active Biotech presenterar på Jefferies 2013 Global Healthcare Conference Regulatory Filings	2013-11-14	Swedish
Active Biotech to Present at the Jefferies 2013 Global Healthcare Conference Regulatory Filings	2013-11-14	English
Active Biotechs valberedning utsedd AGM Information	2013-11-11	Swedish
Active Biotech's election committee appointed Board/Management Information	2013-11-11	English
Interim / Quarterly Report 2013 Interim / Quarterly Report 9M 2013	2013-11-07	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report 9M 2013	2013-11-07	English
Active Biotech AB Delårsrapport januari - september 2013 Interim / Quarterly Report 9M 2013	2013-11-07	Swedish
Active Biotech AB Interim Report January - September 2013 Interim / Quarterly Report 9M 2013	2013-11-07	English
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis Regulatory Filings	2013-11-04	English
Active Biotechs partner Teva startar ytterligare en klinisk studie i multipel skleros Regulatory Filings	2013-11-04	Swedish
Active Biotech receives tasquinimod milestone payment from Ipsen for 10TASQ10 study M&A Activity	2013-10-09	English
Active Biotech erhåller delmålsbetalning från Ipsen för studien 10TASQ10 Regulatory Filings	2013-10-09	Swedish
New Data Presented at 29th ECTRIMS Congress Reinforce the Clinical Profile of Investigational Laquinimod on Disease Progression and Inflammation in Relapsing-Remitting Multiple Sclerosis Investor Presentation	2013-10-04	English
Nya data presenterade på 29th ECTRIMS Congress stärker ytterligare laquinimods kliniska profil vad gäller sjukdomsutveckling och inflammation vid multipel skleros Regulatory Filings	2013-10-04	Swedish
Newly Published Phase III Exploratory Analysis Suggests Investigational Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by Neurodegeneration Earnings Release FY 2013	2013-10-01	English
En ny explorativ fas III-analys visar att den orala läkemedelskandidaten laquinimod för behandling av multipel skleros kan minska skador på hjärnvävnad orsakade av neurodegeneration Regulatory Filings	2013-10-01	Swedish
Active Biotech's project ANYARA will be presented at the European Cancer Congress 2013 Regulatory Filings	2013-09-12	English
Active Biotechs projekt ANYARA presenteras på European Cancer Congress 2013 Investor Presentation	2013-09-12	Swedish
Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference Report Publication Announcement	2013-09-05	English
Active Biotech presenterar på Rodman & Renshaw Annual Global Investment Conference Investor Presentation	2013-09-05	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report H1 2013	2013-08-07	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report H2 2013	2013-08-07	English
Active Biotech AB Delårsrapport januari - juni 2013 Interim / Quarterly Report H1 2013	2013-08-07	Swedish
Active Biotech AB Interim Report January - June 2013 Interim / Quarterly Report H2 2013	2013-08-07	English
ACTIVE BIOTECH OCH TEVA RAPPORTERAR POSITIVA RESULTAT FRÅN FAS IIa-STUDIE AV LAQUINIMOD I AKTIV LUPUS NEFRIT Regulatory Filings	2013-06-12	Swedish
TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS FROM PHASE IIa STUDY OF LAQUINIMOD IN ACTIVE LUPUS NEPHRITIS Regulatory Filings	2013-06-12	English
Active Biotechs läkemedelskandidat tasquinimods effekt på skelettmetastaser presenteras på ASCO Environmental & Social Information	2013-06-03	Swedish
Active Biotech's project ANYARA improved overall survival in a subgroup of renal cell cancer patients Earnings Release FY 2013	2013-06-03	English
Active Biotech presenterar på Jefferies 2013 Global Healthcare Conference Investor Presentation	2013-05-30	Swedish
Active Biotech to Present at the Jefferies 2013 Global Healthcare Conference Report Publication Announcement	2013-05-30	English
Annual General Meeting of Active Biotech AB AGM Information	2013-05-16	English
Årsstämma i Active Biotech AB AGM Information	2013-05-16	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report Q1 2013	2013-04-25	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report Q1 2013	2013-04-25	English
Active Biotech AB Delårsrapport januari - mars 2013 Interim / Quarterly Report Q1 2013	2013-04-25	Swedish
Active Biotech AB Interim Report January - March 2013 Interim / Quarterly Report Q1 2013	2013-04-25	English
Annual Report 2013 Annual Report FY 2013	2013-04-15	Swedish
Annual Report 2012 Active Biotech AB (publ) Report Publication Announcement	2013-04-15	English
Årsredovisning 2012 Active Biotech AB (publ) Report Publication Announcement	2013-04-15	Swedish
Active Biotech - Notice of Annual General Meeting of Shareholders AGM Information	2013-04-11	English
Active Biotech - Kallelse till årsstämma AGM Information	2013-04-11	Swedish
Number of shares and votes in Active Biotech Declaration of Voting Results & Voting Rights Announcements	2013-03-28	English
Antal aktier och röster i Active Biotech Declaration of Voting Results & Voting Rights Announcements	2013-03-28	Swedish
EARLY VERSUS DELAYED TREATMENT WITH LAQUINIMOD DEMONSTRATED SIGNIFICANT REDUCTION IN RISK OF DISABILITY PROGRESSION - RESULTS OF THREE-YEAR ALLEGRO STUDY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS Earnings Release FY 2013	2013-03-21	English
TIDIG BEHANDLINGSSTART MED LAQUINIMOD VISAR SIGNIFIKANT MINDRE RISK FÖR FUNKTIONSNEDSÄTTNING - TREÅRSRESULTAT FRÅN ALLEGRO, EN KLINISK STUDIE I RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS- PATIENTER Earnings Release FY 2013	2013-03-21	Swedish
Major Shareholding Notification 2013 Major Shareholding Notification	2013-03-11	English
FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS Regulatory Filings	2013-03-06	English
FÖRSTA PATIENTEN REKRYTERAD TILL DEN TREDJE FAS III-STUDIEN AV ORAL LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS Regulatory Filings	2013-03-06	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report FY 2012	2013-02-14	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report FY 2012	2013-02-14	English
Active Biotech AB Bokslutsrapport januari - december 2012 Interim / Quarterly Report FY 2012	2013-02-14	Swedish
Active Biotech AB Year-end report January - December 2012 Interim / Quarterly Report FY 2012	2013-02-14	English
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer Earnings Release FY 2013	2013-01-28	English
Resultat från Active Biotechs fas II/III-studie med ANYARA för behandling av njurcancer Earnings Release FY 2013	2013-01-28	Swedish
Active Biotech to Present at the JP Morgan 31st Annual Healthcare Conference Investor Presentation	2013-01-03	English
Active Biotech presenterar på JP Morgan 31st Annual Healthcare Conference Report Publication Announcement	2013-01-03	Swedish

Filings by year

2026 11 filings
2025 41 filings
2024 45 filings
2023 32 filings
2022 42 filings
2021 48 filings
2020 41 filings
2019 45 filings
2018 38 filings
2017 33 filings
2016 40 filings
2015 40 filings
2014 49 filings
2013 58 filings
2012 58 filings
2011 56 filings
2010 62 filings
2009 55 filings
2008 28 filings
2007 8 filings